Zhejiang Hisun Pharmaceutical Co., Ltd.SSE: 600267

Announcement on Expected Increase in Semi-annual Performance for 2026

· Issued by Zhejiang Hisun Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · · 2 pages · Chinese

Summary by 6ix AI

The company anticipates a significant rise in net profit compared to the same period last year, driven by steady growth in its core business segments. Factors contributing to this increase include improved sales of innovative drugs and cost reductions due to enhanced operational efficiency. The announcement also includes a risk warning, stating no significant uncertainties have been identified that could impact the forecast.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Release

Announcement on Expected Increase in Semi-annual Performance for 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:

Zhejiang Hisun Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang Hisun Pharmaceutical

Later from Zhejiang Hisun Pharmaceutical

All Zhejiang Hisun Pharmaceutical news releases